Overall, these findings reveal a critical interplay between adipocyte‐mediated metabolic reprogramming and EIF3H‐mediated YAP proteolytic control, offering promising therapeutic strategies to mitigate the adverse effects of obesity on TNBC progression. This evidence concerns the gene EIF3H and obesity due to melanocortin 4 receptor deficiency.